A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael...
-
Upload
hannah-bruce -
Category
Documents
-
view
214 -
download
1
Transcript of A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael...
![Page 1: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/1.jpg)
A Generalised Model for Valuing Early
Stage Technology
Palisade Europe User Conference
2008
Michael Brand
© 2008 Captum Capital Limited
![Page 2: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/2.jpg)
2
About Captum…• Formed in 2004
• Transatlantic presence
• Specialised consulting to:– Private companies (pre-IPO)– Life science sector (Biotech, Med Dev, Pharma)– Business development, valuation, partnering
• MasterClasses in Finance, Leadership– Valuation Masterclass attended by over 350
executives in UK and Europe
![Page 3: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/3.jpg)
3
Valuing Technology
• Technical Risk– Will it work?– Scale up issues– Regulatory hurdles
• Market Risk– Customer acceptance– Pricing issues– Competition
![Page 4: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/4.jpg)
4
Valuing Risk
£ X£200,000
£0
0.5
0.5or
What value of “X” are you indifferent between a fixed sum and playing the game?
£1
£1,000
£10,000
£20,000
£50,000
£100,000
![Page 5: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/5.jpg)
5
Valuing Technology
Early-stage Technology Company
Development Cost
NPV Success
NPV Failure
![Page 6: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/6.jpg)
6
Valuation Parameters
• Cash Flow• Probability of achieving cash flow• Discount rate (less uncertain)
Cs
Cf
P
(1 – P)
t
f
ts
r
CP
r
PCeNPV
)1(
)1(
)1(
t
![Page 7: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/7.jpg)
7
Stepwise Development
Concept Development Manufacturing Market launch
Development can fail at any milestone along the development pathway
![Page 8: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/8.jpg)
8
Drug Discovery Process
Pre-Clinical
Phase 1 Phase 2 Phase 3 FDA
S
F
S
S
SS
FF
FF
![Page 9: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/9.jpg)
9
General Value Model
Risk Adjusted NPV =
Risk Adjusted NPV Sales Income
Risk Adjusted NPV Development Cost
+
![Page 10: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/10.jpg)
10
Case: ReJuven8
• Innovative wound care treatment• Demonstrated on animals, limited human trial• Requires manufacturing scale-up for:
– Small and Large scale human clinical trials– FDA Approval
• Post FDA approval, sales launch
This case has been written by Captum Capital Limited for educational purposes only. Any resemblance to any actual person, company, organization or technology is entirely accidental. Data included in this case is for illustration only, and should not be relied on for accuracy.
![Page 11: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/11.jpg)
11
ReJuven8 Development
Scale up CT1 CT2 FDA
0.7
0.4
0.6
0.9
0.5
0.1
1.2
0.2
1.5
0.2
0.5
0.3
Cash Flow $m
Overall Probability of FDA Approval = 0.15
![Page 12: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/12.jpg)
12
ReJuven8 PreSales Model
![Page 13: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/13.jpg)
13
Binary Decisions
![Page 14: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/14.jpg)
14
ReJuven8 Presales NPV
![Page 15: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/15.jpg)
15
Forecasting SalesTop Down
Bottom Up
• Total Market Size ($/yr)
• Market Share (%)
• Price/unit ($/unit)
• User Penetration (%)
• Potential Users (units)
Sales
![Page 16: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/16.jpg)
16
Market PenetrationPt = K Po ekt
K + Po (ekt – 1)
P0=1
K=10
Pt
Time, t
a b c
k
a = 2
b = 1
c = 0.5
Verhulst Pearl Equation
![Page 17: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/17.jpg)
17
Adding Post Launch SalesReJuven8 Sales Forecast
0
2
4
6
8
10
1 2 3 4 5
Year
Net
Cas
h Fl
ow $
m
![Page 18: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/18.jpg)
18
ReJuven8 Post Sales NPV
![Page 19: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/19.jpg)
19
Year 1 Sales Distribution
![Page 20: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/20.jpg)
20
ReJuven8 3 Year Sales
![Page 21: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/21.jpg)
21
ReJuven8 5 Year Sales
![Page 22: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/22.jpg)
22
Summary• Model Advantages
– Graphical depiction of technology/market risk– Flexible: facilitates development strategy – Intuitive: based on realistic probabilities – Effective communication tool
• Downside– Valuing very early stage technology difficult– Most investors are risk adverse (<eNPV)– Requires analytical discipline
![Page 23: A Generalised Model for Valuing Early Stage Technology Palisade Europe User Conference 2008 Michael Brand © 2008 Captum Capital Limited.](https://reader035.fdocuments.us/reader035/viewer/2022070305/55141cfb5503466d1a8b468a/html5/thumbnails/23.jpg)
23
Contact
Michael Brande: [email protected]
t: +44 (0) 115 988 6154
m: +44 (0) 7980 257 241
Captum Capital LimitedCumberland House
35 Park Row
Nottingham NG1 6EE
United Kingdom